← All trials
NCT05253209
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2022
- Primary completion
- Jun 15, 2023
- Completion date
- Aug 10, 2023
- First posted
- Feb 23, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 97
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AsklepionLead sponsor
- Indiana UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.